Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1994-11-15
1999-03-16
Kishore, Gollamudi S.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
514573, 514825, 514866, A61K 9127
Patent
active
058826785
ABSTRACT:
This invention provides an interdigitation-fusion liposome comprising an arachidonic acid metabolite, a lipid bilayer comprising a lipid and an aqueous compartment comprising a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE.sub.1. The liposomal formulations can be used to treat animals, particularly humans, for diseases, disorders or conditions which can be ameliorated by prostaglandins, e.g., cell activation/adhesion disorders and inflammatory disorders.
REFERENCES:
patent: 4229360 (1980-10-01), Schneider et al.
patent: 4493847 (1985-01-01), Mizishuma et al.
patent: 4684633 (1987-08-01), Imagawa et al.
patent: 4820732 (1989-04-01), Shell et al.
patent: 4837028 (1989-06-01), Allen et al.
patent: 4880635 (1989-11-01), Janoff et al.
patent: 4920016 (1990-04-01), Allen et al.
patent: 4955878 (1990-09-01), See et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5077056 (1991-12-01), Bally et al.
patent: 5262168 (1993-11-01), Leuk
patent: 5283122 (1994-02-01), Huang
Blume, et al., "Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times", Biochem. Biophy. Acta. 1149:180-184, 1993.
Gabizon, et al., "Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs", Pharm. Res. 10(5):703, 1993.
Goodman and Gilman's The Pharmacological Basis of Therapeutics, Goodman gilman et al., eds. Pergamon Press, New York, 1990, pp. 600-611.
Hoshi, et al., "Prostaglandin E.sub.1 Incorporated in Lipid Microspheres in the Treatment of Peripheral Vaculare Diseases and Diabetic Neuropathy", Drugs. Exptl. Clin Res. 12 (8):681, 1986.
Mizishuma et al., "A Multicenter Double Blind Controlled Study of Lipo-PGE.sub.1, PGE .sub.1 Incorporated in Lipid Microsopheres, in Peripheral Vascular Disease Secondary to Connective Tissue Disorders", J. Rheumatol. 14:97 (1987).
Park et al., "Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo", Biochim. Biophys Acta. 1108: 257, 1992.
Stedman's Medical Distionary (Illustrated), (24th edition J. V. Basmajian et al., eds.) Williams and Wilkins, Baltimore, MD, 1982, pp. 123-124 and 707-708.
Stryer, Biochemistry (2nd edition), W. H. Freeman and Co. New York 1981, pp. 853-854.
"Adhesion in Disease and Therapy,", (Springer et al., eds.) in: Leukocyte Adhesion Molecules, Springer-Verlag, New York, (1990) pp. 85-156.
Janoff Andrew S.
Minchey Sharma R.
Kishore Gollamudi S.
Rubin Kenneth B.
The Liposome Co, Inc.
LandOfFree
Interdigitation-fusion liposomes containing arachidonic acid met does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interdigitation-fusion liposomes containing arachidonic acid met, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interdigitation-fusion liposomes containing arachidonic acid met will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-814990